(firstQuint)Study to Assess the Immunogenicity and Safety of Etanercept Produced Using a Modified Process in Patients With Plaque Psoriasis.

 This is a multicenter, open-label, single-arm phase 4 study in patients with plaque psoriasis who are etanercept-naive and who are not receiving methotrexate therapy.

 The study will consist of a screening period of up to 30 days, a 24-week treatment period and a 30-day follow-up period for safety.

 Etanercept dosing will follow the recommended label dosing for patients with plaque psoriasis.

.

 Study to Assess the Immunogenicity and Safety of Etanercept Produced Using a Modified Process in Patients With Plaque Psoriasis@highlight

The purpose of this study is to learn more about the immune response to etanercept produced using a modified process in patients with plaque psoriasis.

